Codexis (NASDAQ:CDXS) Issues Earnings Results

Codexis (NASDAQ:CDXS) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05), Zacks reports. The company had revenue of $7.54 million for the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. Codexis updated its FY 2025 guidance to EPS.

Codexis Stock Performance

Shares of CDXS opened at $2.51 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The stock has a market capitalization of $207.94 million, a P/E ratio of -2.89 and a beta of 2.56. The company’s fifty day moving average is $2.44 and its two-hundred day moving average is $3.74. Codexis has a 1 year low of $1.90 and a 1 year high of $6.08.

Hedge Funds Weigh In On Codexis

A hedge fund recently raised its stake in Codexis stock. Royal Bank of Canada raised its position in Codexis, Inc. (NASDAQ:CDXS) by 24.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 437,126 shares of the biotechnology company’s stock after buying an additional 87,044 shares during the quarter. Royal Bank of Canada owned about 0.53% of Codexis worth $1,176,000 as of its most recent filing with the SEC. Institutional investors own 78.54% of the company’s stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.